• 1
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118.
  • 2
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
  • 3
    National Center for Health Statistics. Healthy People 2000 Review, 1995-1996. Hyattsville, MD: Public Health Service; 1996.
  • 4
    Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442.
  • 5
    Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Financ Rev 1985;7:61-70.
  • 6
    Thein HH, Isaranuwatchai W, Campitelli MA, Feld JJ, Yoshida E, Sherman M, et al. Healthcare costs associated with hepatocellular carcinoma: a population-based study. Hepatology 2013;58:1375-1384.
  • 7
    Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630-641.
  • 8
    Lang HC, Wu JC, Yen SH, Lan CF, Wu SL. The lifetime cost of hepatocellular carcinoma: a claims data analysis from a medical centre in Taiwan. Appl Health Econ Health Policy 2008;6:55-65.
  • 9
    Porter ME. What is value in health care? N Engl J Med 2010;363:2477-2481.
  • 10
    Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.